JP2022520081A5 - - Google Patents
Info
- Publication number
- JP2022520081A5 JP2022520081A5 JP2021546894A JP2021546894A JP2022520081A5 JP 2022520081 A5 JP2022520081 A5 JP 2022520081A5 JP 2021546894 A JP2021546894 A JP 2021546894A JP 2021546894 A JP2021546894 A JP 2021546894A JP 2022520081 A5 JP2022520081 A5 JP 2022520081A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- tada
- protein according
- adenosine deaminase
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025093886A JP2025143279A (ja) | 2019-02-13 | 2025-06-05 | アデノシンデアミナーゼ塩基エディターおよびそれを用いて標的配列中の核酸塩基を改変する方法 |
Applications Claiming Priority (33)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805271P | 2019-02-13 | 2019-02-13 | |
| US201962805277P | 2019-02-13 | 2019-02-13 | |
| US201962805238P | 2019-02-13 | 2019-02-13 | |
| US62/805,277 | 2019-02-13 | ||
| US62/805,271 | 2019-02-13 | ||
| US62/805,238 | 2019-02-13 | ||
| US201962852228P | 2019-05-23 | 2019-05-23 | |
| US201962852224P | 2019-05-23 | 2019-05-23 | |
| US62/852,224 | 2019-05-23 | ||
| US62/852,228 | 2019-05-23 | ||
| US201962873138P | 2019-07-11 | 2019-07-11 | |
| US201962873144P | 2019-07-11 | 2019-07-11 | |
| US201962873140P | 2019-07-11 | 2019-07-11 | |
| US62/873,138 | 2019-07-11 | ||
| US62/873,140 | 2019-07-11 | ||
| US62/873,144 | 2019-07-11 | ||
| US201962876354P | 2019-07-19 | 2019-07-19 | |
| US62/876,354 | 2019-07-19 | ||
| US201962888867P | 2019-08-19 | 2019-08-19 | |
| US62/888,867 | 2019-08-19 | ||
| US201962912992P | 2019-10-09 | 2019-10-09 | |
| US62/912,992 | 2019-10-09 | ||
| US201962931722P | 2019-11-06 | 2019-11-06 | |
| US201962931747P | 2019-11-06 | 2019-11-06 | |
| US62/931,722 | 2019-11-06 | ||
| US62/931,747 | 2019-11-06 | ||
| US201962941569P | 2019-11-27 | 2019-11-27 | |
| US201962941523P | 2019-11-27 | 2019-11-27 | |
| US62/941,523 | 2019-11-27 | ||
| US62/941,569 | 2019-11-27 | ||
| US202062966526P | 2020-01-27 | 2020-01-27 | |
| US62/966,526 | 2020-01-27 | ||
| PCT/US2020/018192 WO2020168132A1 (en) | 2019-02-13 | 2020-02-13 | Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequence |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093886A Division JP2025143279A (ja) | 2019-02-13 | 2025-06-05 | アデノシンデアミナーゼ塩基エディターおよびそれを用いて標的配列中の核酸塩基を改変する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022520081A JP2022520081A (ja) | 2022-03-28 |
| JP2022520081A5 true JP2022520081A5 (cg-RX-API-DMAC7.html) | 2023-02-17 |
| JP7693552B2 JP7693552B2 (ja) | 2025-06-17 |
Family
ID=72043868
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546894A Active JP7693552B2 (ja) | 2019-02-13 | 2020-02-13 | アデノシンデアミナーゼ塩基エディターおよびそれを用いて標的配列中の核酸塩基を改変する方法 |
| JP2025093886A Pending JP2025143279A (ja) | 2019-02-13 | 2025-06-05 | アデノシンデアミナーゼ塩基エディターおよびそれを用いて標的配列中の核酸塩基を改変する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093886A Pending JP2025143279A (ja) | 2019-02-13 | 2025-06-05 | アデノシンデアミナーゼ塩基エディターおよびそれを用いて標的配列中の核酸塩基を改変する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20220170027A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3924479A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7693552B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210139265A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114072496A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020221366A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3129158A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020168132A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3765615T3 (pl) | 2018-03-14 | 2023-11-13 | Arbor Biotechnologies, Inc. | Nowe enzymy i układy crispr ukierunkowane na dna |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| WO2019222555A1 (en) | 2018-05-16 | 2019-11-21 | Arbor Biotechnologies, Inc. | Novel crispr-associated systems and components |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| JP7646552B2 (ja) | 2019-01-31 | 2025-03-17 | ビーム セラピューティクス インク. | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
| WO2020168135A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| EP3924479A4 (en) * | 2019-02-13 | 2023-01-25 | Beam Therapeutics, Inc. | ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE |
| CN114096666B (zh) | 2019-02-13 | 2025-03-18 | 比姆医疗股份有限公司 | 治疗血红素病变的组合物和方法 |
| JP7600208B2 (ja) | 2019-07-29 | 2024-12-16 | ジョージア テック リサーチ コーポレイション | 拘束された脂質を含むナノ材料およびその使用 |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| CN115175894B (zh) | 2020-01-09 | 2024-09-06 | 盖德治疗有限责任公司 | 纳米材料 |
| CN116113692A (zh) * | 2020-02-13 | 2023-05-12 | 比姆医疗股份有限公司 | 用于植入碱基编辑细胞的组合物和方法 |
| CN115698278B (zh) * | 2020-03-31 | 2025-10-17 | 阿伯生物技术公司 | 包含Cas12i2变体多肽的组合物及其用途 |
| KR20230061474A (ko) * | 2020-09-04 | 2023-05-08 | 고쿠리츠다이가쿠호진 고베다이가쿠 | 소형화 시티딘 데아미나아제를 포함하는 이중쇄 dna의 개변용 복합체 |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| WO2022119295A1 (ko) * | 2020-12-01 | 2022-06-09 | 한양대학교 산학협력단 | 티민-사이토신 서열 특이적 사이토신 교정 활성이 증진된 아데닌 염기교정 유전자가위 및 이의 용도 |
| US20240002834A1 (en) * | 2020-12-01 | 2024-01-04 | Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) | Adenine base editor lacking cytosine editing activity and use thereof |
| EP4281080A4 (en) | 2021-01-20 | 2025-09-24 | Beam Therapeutics Inc | NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT |
| CN116761888A (zh) | 2021-01-20 | 2023-09-15 | 比姆医疗股份有限公司 | 纳米材料 |
| CN115704015B (zh) * | 2021-08-12 | 2025-08-12 | 清华大学 | 基于腺嘌呤和胞嘧啶双碱基编辑器的靶向诱变系统 |
| CN115772512B (zh) * | 2021-09-07 | 2025-12-23 | 华东师范大学 | 腺嘌呤脱氨酶、包含其的腺嘌呤碱基编辑器及其应用 |
| EP4409000A1 (en) | 2021-09-28 | 2024-08-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Base editing approaches for the treatment of beta-hemoglobinopathies |
| CN114045277B (zh) * | 2021-10-21 | 2024-11-05 | 复旦大学 | 碱基编辑器及其构建方法与应用 |
| CN114058639B (zh) * | 2021-10-29 | 2023-11-07 | 中国种子集团有限公司 | 利用单碱基基因编辑技术突变OsWaxy基因改良水稻直链淀粉含量的方法 |
| WO2023099591A1 (en) | 2021-12-01 | 2023-06-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for increasing fetal hemoglobin content by editing the +55-kb region of the erythroid-specific bcl11a enhancer |
| WO2023121971A1 (en) | 2021-12-20 | 2023-06-29 | Beam Therapeutics Inc. | Nanomaterials comprising tetravalent lipid compounds |
| WO2023121965A1 (en) | 2021-12-20 | 2023-06-29 | Beam Therapeutics Inc. | Nanomaterial comprising diamines |
| WO2023121970A1 (en) | 2021-12-20 | 2023-06-29 | Beam Therapeutics Inc. | Ionizable amine and ester lipids and lipid nanoparticles |
| CA3241488A1 (en) | 2021-12-20 | 2023-06-29 | Beam Therapeutics Inc. | Ionizable amine lipids and lipid nanoparticles |
| WO2023121964A1 (en) | 2021-12-20 | 2023-06-29 | Beam Therapeutics Inc. | Nanomaterials comprising disulfides |
| WO2023144104A1 (en) | 2022-01-25 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Base editing approaches for the treatment of βeta-thalassemia |
| CN117187220A (zh) * | 2022-03-08 | 2023-12-08 | 中国科学院遗传与发育生物学研究所 | 腺嘌呤脱氨酶及其在碱基编辑中的用途 |
| CN114634923B (zh) * | 2022-04-07 | 2024-02-23 | 尧唐(上海)生物科技有限公司 | 腺苷脱氨酶、碱基编辑器融合蛋白、碱基编辑器系统及用途 |
| CN120456933A (zh) | 2022-04-28 | 2025-08-08 | 布罗德研究所股份有限公司 | 编码碱基编辑器的aav载体及其用途 |
| JP2025517657A (ja) | 2022-05-10 | 2025-06-10 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | シンシチン-1融合タンパク質及び標的細胞へのカーゴ送達のためのその使用 |
| CN114686456B (zh) | 2022-05-10 | 2023-02-17 | 中山大学 | 基于双分子脱氨酶互补的碱基编辑系统及其应用 |
| WO2023217888A1 (en) | 2022-05-10 | 2023-11-16 | Institut National de la Santé et de la Recherche Médicale | Base editing approaches for correcting the cd39 (cag>tag) mutation in patients suffering from βeta-thalassemia |
| KR20250037788A (ko) * | 2022-06-15 | 2025-03-18 | 빔 테라퓨틱스, 인크. | 보체 활성화를 감소시키기 위한 조성물 및 방법 |
| EP4543469A4 (en) * | 2022-06-27 | 2026-06-03 | Beam Therapeutics Inc | COMPOSITIONS AND CONDITIONING METHODS OF NON-GENOTOXIC CELLS |
| EP4540222A1 (en) | 2022-07-20 | 2025-04-23 | Beam Therapeutics Inc. | Nanomaterials comprising triols |
| WO2024018056A1 (en) | 2022-07-22 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Base editing approaches for correcting the ivs2-1 (g>a) mutation in patients suffering from βeta-thalassemia |
| WO2024086596A1 (en) * | 2022-10-18 | 2024-04-25 | 4M Genomics Inc. | Polypeptide fusions or conjugates for gene editing |
| WO2024165484A1 (en) | 2023-02-06 | 2024-08-15 | Institut National de la Santé et de la Recherche Médicale | Enrichment of genetically modified hematopoietic stem cells through multiplex base editing |
| WO2024229240A2 (en) * | 2023-05-03 | 2024-11-07 | Beam Therapeutics Inc. | Compositions and methods for treating stargardt disease |
| WO2024230760A1 (zh) * | 2023-05-09 | 2024-11-14 | 北京齐禾生科生物科技有限公司 | 一种可作用于dna的腺苷脱氨酶及其应用 |
| CN118871578A (zh) * | 2023-05-24 | 2024-10-29 | 锐正基因(苏州)有限公司 | 用于碱基编辑的脱氨酶及其变体 |
| WO2025038821A1 (en) * | 2023-08-16 | 2025-02-20 | Chroma Medicine, Inc. | Methods and compositions for multiplex epigenetic editing |
| EP4777618A1 (en) * | 2023-09-15 | 2026-07-22 | Beam Therapeutics Inc. | Compositions and methods for base editing a phenylalanine hydroxylase polynucleotide |
| KR20260094824A (ko) | 2023-10-25 | 2026-06-23 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 고효율, 저오프타겟 유전자 편집 도구 |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| CN120290534A (zh) * | 2024-01-10 | 2025-07-11 | 上海数因信科智能科技有限公司 | 腺嘌呤脱氨酶、包含其的碱基编辑器融合蛋白和碱基编辑器系统及其应用 |
| CN117568313B (zh) * | 2024-01-15 | 2024-04-26 | 上海贝斯昂科生物科技有限公司 | 基因编辑组合物及其用途 |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025202473A1 (en) * | 2024-03-28 | 2025-10-02 | Revvity Discovery Limited | A nucleic acid deaminase, a base editor and uses thereof |
| US20250332260A1 (en) | 2024-04-10 | 2025-10-30 | Garuda Therapeutics, Inc. | Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations |
| WO2025228273A1 (zh) * | 2024-04-28 | 2025-11-06 | 广州瑞风生物科技有限公司 | 脱氨酶、单碱基编辑器及其应用 |
| WO2026060637A1 (en) * | 2024-09-20 | 2026-03-26 | Shanghai Vitalgen Biopharma Co., Ltd. | Engineered mrna for gene editing using crispr/cas12b |
| WO2026096539A1 (en) | 2024-10-28 | 2026-05-07 | Beam Therapeutics Inc. | Secondary alcohol lipids |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150166984A1 (en) * | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| EP4019975A1 (en) * | 2015-04-24 | 2022-06-29 | Editas Medicine, Inc. | Evaluation of cas9 molecule/guide rna molecule complexes |
| US11008555B2 (en) * | 2015-09-17 | 2021-05-18 | The Regents Of The University Of California | Variant Cas9 polypeptides comprising internal insertions |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| US11180778B2 (en) * | 2016-11-11 | 2021-11-23 | The Regents Of The University Of California | Variant RNA-guided polypeptides and methods of use |
| EP3625342B1 (en) * | 2017-05-18 | 2022-08-24 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| US10392616B2 (en) * | 2017-06-30 | 2019-08-27 | Arbor Biotechnologies, Inc. | CRISPR RNA targeting enzymes and systems and uses thereof |
| WO2020163396A1 (en) | 2019-02-04 | 2020-08-13 | The General Hospital Corporation | Adenine dna base editor variants with reduced off-target rna editing |
| EP3924479A4 (en) * | 2019-02-13 | 2023-01-25 | Beam Therapeutics, Inc. | ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE |
| WO2020168135A1 (en) * | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| CN114096666B (zh) * | 2019-02-13 | 2025-03-18 | 比姆医疗股份有限公司 | 治疗血红素病变的组合物和方法 |
| JP7679311B2 (ja) * | 2019-05-21 | 2025-05-19 | ビーム セラピューティクス インク. | プログラム可能塩基エディターシステムを用いた一塩基多型編集法 |
-
2020
- 2020-02-13 EP EP20755422.1A patent/EP3924479A4/en active Pending
- 2020-02-13 CN CN202080028658.7A patent/CN114072496A/zh active Pending
- 2020-02-13 AU AU2020221366A patent/AU2020221366A1/en active Pending
- 2020-02-13 WO PCT/US2020/018192 patent/WO2020168132A1/en not_active Ceased
- 2020-02-13 KR KR1020217029282A patent/KR20210139265A/ko active Pending
- 2020-02-13 CA CA3129158A patent/CA3129158A1/en active Pending
- 2020-02-13 JP JP2021546894A patent/JP7693552B2/ja active Active
- 2020-02-13 US US17/430,669 patent/US20220170027A1/en active Pending
- 2020-12-18 US US17/127,630 patent/US11155803B2/en active Active
-
2023
- 2023-10-13 US US18/486,913 patent/US20240132867A1/en not_active Abandoned
-
2025
- 2025-06-05 JP JP2025093886A patent/JP2025143279A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022519882A5 (cg-RX-API-DMAC7.html) | ||
| JP2025170240A5 (cg-RX-API-DMAC7.html) | ||
| JP2022546608A5 (cg-RX-API-DMAC7.html) | ||
| JP2022519507A5 (cg-RX-API-DMAC7.html) | ||
| JP2022533673A5 (cg-RX-API-DMAC7.html) | ||
| Tanaka et al. | Analysis of a human DNA excision repair gene involved in group A xeroderma pigmentosum and containing a zinc-finger domain | |
| JP2025102784A5 (cg-RX-API-DMAC7.html) | ||
| Itoh et al. | Cloning of Drosophila choline acetyltransferase cDNA. | |
| Kanazawa et al. | Nucleotide sequence of the genes for β and ε subunits of proton-translocating ATPase from Escherichia coli | |
| CA2222279A1 (en) | Hypoxia inducible factor-1 and method of use | |
| AU764571B2 (en) | 5' ESTs and encoded human proteins | |
| Sogawa et al. | Complete nucleotide sequence of a methylcholanthrene-inducible cytochrome P-450 (P-450d) gene in the rat. | |
| JP2022519761A5 (cg-RX-API-DMAC7.html) | ||
| IE66307B1 (en) | Recombinant human endothelial cell growth factor | |
| EA003086B1 (ru) | ПОЛИПЕПТИДЫ LAG-3V1, LAG-3V2 И LAG-3V3 И КОДИРУЮЩИЕ ИХ кДНК | |
| IE61773B1 (en) | Novel lymphokine related peptides | |
| JP2021536250A5 (cg-RX-API-DMAC7.html) | ||
| Angulo et al. | Identification and expression of the cDNA of KIN17, a zinc-finger gene located on mouse chromosome 2, encoding a new DNA-binding protein | |
| JP2022542294A5 (cg-RX-API-DMAC7.html) | ||
| Saito et al. | Cloning of a full-length cDNA encoding bovine thymus poly (ADP-ribose) synthetase: evolutionarily conserved segments and their potential functions | |
| Takasawa et al. | Novel gene activated in rat insulinomas | |
| JP2005245469A (ja) | 腫瘍サプレッサ遺伝子、並びに癌の検出、腫瘍進行のモニタおよび癌処置のための方法 | |
| JP2022526670A5 (cg-RX-API-DMAC7.html) | ||
| Csordás-Tóth et al. | Structure of the promoter region for the rrnB gene in Eacherichia coli | |
| PT99929A (pt) | Processo para a preparacao de cadeias alfa recombinantes do receptor humano da interleucina 5 e de composicoes farmaceuticas que as contem |